^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
New
Title:

Senhwa’s Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations

Published date:
01/24/2022
Excerpt:
Senhwa Biosciences, Inc....announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for Pidnarulex, a first-in-class G-quadruplex stabilizer, for the treatment of patients with breast and ovarian cancers BRCA1/2, PALB2, or other HRD mutations.